SCHEDULE: Deep Track Capital Boosts X4 Pharma Stake to 9.99%

Deep Track Capital and affiliates have disclosed a 9.99% beneficial ownership stake in X4 Pharmaceuticals, Inc., holding 2,366,995 shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 2,366,995 shares of X4 Pharmaceuticals, Inc. Common Stock.
• This represents 9.99% of the company's outstanding common stock.
• The ownership includes 4,162,137 Pre-Funded Warrants exercisable into common shares, subject to a 9.99% maximum exercise limitation.
• The calculation of the percentage is based on 23,693,644 shares, which includes 11,408,357 common shares outstanding as of August 4, 2025, and 1,244,511 common shares convertible by the reporting person up to the maximum percentage.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 7

Explanation: The filing indicates a significant, near-10% stake by a specialized institutional investor, Deep Track Capital, in X4 Pharmaceuticals. This suggests a strong vote of confidence and potential long-term interest in the company's prospects, which is generally positive for existing shareholders. The passive nature of the investment (13G filing) means no immediate activist intent, which can be seen as stable.

Positives

• A significant institutional investor, Deep Track Capital, has taken a substantial stake, potentially signaling confidence in X4 Pharmaceuticals' future prospects.
• The investment includes pre-funded warrants, indicating a strategic entry point and potential for future conversion.

Negatives

• The 9.99% maximum percentage exercise limitation on Pre-Funded Warrants means the holder cannot exercise portions of the warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding common stock, potentially limiting their ability to fully convert their investment.

Risks

• The 9.99% maximum percentage exercise limitation on Pre-Funded Warrants means the holder cannot exercise portions of the warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding common stock, potentially limiting their ability to fully convert their investment.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by a specialized biotechnology fund, Deep Track Capital, into X4 Pharmaceuticals, a company likely operating within the biotechnology or pharmaceutical sector. Such investments are common in the biotech industry, where specialized funds seek to capitalize on potential drug development milestones or market opportunities. The acquisition of a near-10% stake suggests a strong belief in the company's long-term value proposition within its specific therapeutic area.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a large stake could be viewed positively, potentially increasing investor confidence and attracting further institutional interest.

Key Dates

Recommendation

The filing indicates a significant, passive investment by Deep Track Capital, a specialized biotechnology fund, acquiring a 9.99% stake in X4 Pharmaceuticals. This signals a vote of confidence from a sophisticated investor, which is generally a positive indicator. However, a Schedule 13G filing does not provide detailed operational or financial performance data, nor does it outline specific strategic initiatives or future catalysts for the company. Therefore, while the institutional backing is favorable, there isn't sufficient new fundamental information to change an existing investment thesis. For current investors, maintaining their position ('hold') is a reasonable approach, awaiting further operational updates or financial results from X4 Pharmaceuticals to reassess the investment.

Keywords

X4 Pharmaceuticals, Deep Track Capital, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Biotechnology, Institutional Investor, SEC Filing